TWI600438B - Method of hydrogel sheet for wound - Google Patents
Method of hydrogel sheet for wound Download PDFInfo
- Publication number
- TWI600438B TWI600438B TW100133462A TW100133462A TWI600438B TW I600438 B TWI600438 B TW I600438B TW 100133462 A TW100133462 A TW 100133462A TW 100133462 A TW100133462 A TW 100133462A TW I600438 B TWI600438 B TW I600438B
- Authority
- TW
- Taiwan
- Prior art keywords
- wound
- water
- hydrogel
- polyacrylic acid
- skin
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims description 78
- 238000000034 method Methods 0.000 title description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 139
- 241000894006 Bacteria Species 0.000 claims description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229920002125 Sokalan® Polymers 0.000 claims description 23
- 230000035699 permeability Effects 0.000 claims description 18
- 239000004584 polyacrylic acid Substances 0.000 claims description 18
- 229920003169 water-soluble polymer Polymers 0.000 claims description 15
- 235000011187 glycerol Nutrition 0.000 claims description 14
- 229920006264 polyurethane film Polymers 0.000 claims description 13
- 239000000835 fiber Substances 0.000 claims description 12
- 206010072170 Skin wound Diseases 0.000 claims description 10
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 230000036961 partial effect Effects 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 241000978776 Senegalia senegal Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 206010052428 Wound Diseases 0.000 description 130
- 210000003491 skin Anatomy 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 28
- 238000012360 testing method Methods 0.000 description 25
- 210000000416 exudates and transudate Anatomy 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 18
- 230000001338 necrotic effect Effects 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 230000000052 comparative effect Effects 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000000499 gel Substances 0.000 description 16
- 239000011248 coating agent Substances 0.000 description 15
- 238000000576 coating method Methods 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 239000000853 adhesive Substances 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 12
- 206010040844 Skin exfoliation Diseases 0.000 description 11
- -1 polypropylene Polymers 0.000 description 11
- 230000001070 adhesive effect Effects 0.000 description 9
- 230000029663 wound healing Effects 0.000 description 9
- 230000035876 healing Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000036074 healthy skin Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000008733 trauma Effects 0.000 description 6
- 230000010388 wound contraction Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 239000002657 fibrous material Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 230000036556 skin irritation Effects 0.000 description 4
- 231100000475 skin irritation Toxicity 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010030 laminating Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 229920006267 polyester film Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035752 proliferative phase Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000035602 clotting Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920005749 polyurethane resin Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IRPGOXJVTQTAAN-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropanal Chemical compound FC(F)(F)C(F)(F)C=O IRPGOXJVTQTAAN-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- KLZUFWVZNOTSEM-UHFFFAOYSA-K Aluminum fluoride Inorganic materials F[Al](F)F KLZUFWVZNOTSEM-UHFFFAOYSA-K 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010027465 Metastases to skin Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010048625 Skin maceration Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108010086613 Streptodornase and Streptokinase Proteins 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- OIXVKQDWLFHVGR-WQDIDPJDSA-N neomycin B sulfate Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO OIXVKQDWLFHVGR-WQDIDPJDSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960004533 streptodornase Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229920006302 stretch film Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A61F13/01017—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
Description
本發明係關於對於併發感染症、或即使尚未至感染,但可認為與感染、細菌菌落化成邊緣狀態之極限帶菌狀態之皮膚創傷患處,具有去除因細菌所形成之生物被膜的作用、自感染創傷去除細菌的作用及/或抑制預測會有感染之創傷的細菌生長發育之作用、以及吸收滲出液等之防止包含創傷邊緣之健康皮膚之浸軟或細菌等感染,同時藉由創傷患處之優異的水份調整性,進行傷口床環境調整,進而追隨性及伸縮性優異,具有自我黏著性,可避免交換時之疼痛或再生皮膚之再度損傷之創傷用水凝膠薄片及其利用方法。The present invention relates to a skin wound affected area which is considered to be a concomitant infectious disease, or which is considered to be in a state of extreme infection with an infection or a bacterial colony, even if it is not yet infected, and has a function of removing a biofilm formed by bacteria and self-infecting wounds. The effect of removing bacteria and/or inhibiting the growth and development of bacteria that are expected to have wounds of infection, and the absorption of exudates and the like to prevent infections such as maceration or bacteria of healthy skin containing wound edges, and at the same time, excellent by the wounds The water-adjustability, the wound bed environment is adjusted, and the follow-up and stretchability are excellent, and the self-adhesive property can be avoided, and the wound hydrogel sheet and the utilization method thereof can be avoided by avoiding pain during exchange or re-injury of the regenerated skin.
另外,關於貼附相關的創傷用水凝膠薄片於創傷等患處,去除無活性的組織、痂皮或生物被膜等,抑制感染、調整傷口床環境等,藉由進行調整傷口床環境,有效地改善創傷治癒環境之治療創傷的方法。In addition, the wound hydrogel sheet attached to the wound is removed from the affected area such as a wound, and the inactive tissue, the molting or the biofilm is removed, the infection is suppressed, the wound bed environment is adjusted, and the like, and the wound bed environment is adjusted to effectively improve the wound bed environment. A method of treating wounds in a wound healing environment.
所謂傷口床環境調整(would bed preparation)係為促進創傷治癒而調整傷口床環境,具體上,進行去除壞死組織、減輕細菌負擔、防止創傷乾燥、控制過多的滲出液或傷口邊緣管理。The so-called wound bed environment adjustment (Woster bed preparation) adjusts the wound bed environment to promote wound healing, specifically, removing necrotic tissue, reducing bacterial burden, preventing wound drying, controlling excessive exudate or wound edge management.
創傷的治癒過程一般係以(1)出血凝固期、(2)發炎期、(3)增殖期、(4)成熟期進行,(1)出血凝固期係由凝固因子或血小板所止血,由血小板釋出血小板來源增殖因子等之增殖因子‧細胞激素(cytokine)。接著,(2)發炎期係由此等因子引起嗜中性球或巨噬細胞(macrophage)等之發炎細胞浸潤,吞噬壞死組織而清淨創傷。同時可見由此等細胞進一步連續地釋出轉化生長因子(transforming growth factor-β,TGF-β)或纖維母細胞生長因子(fibroblast growth factor,FGF)等之增殖因子‧細胞激素。另外,為融解壞死組織蛋白質,亦釋出基質金屬蛋白酵素(matrix metalloproteinase,MMP)等之蛋白酶類。隨著創傷的清淨化,移向(3)增殖期。(2)階段所釋出的因子係促進纖維母細胞(Fibroblast)或角質細胞(keratinocyte)等之移動、增殖。由纖維母細胞合成膠原蛋白所代表之細胞外基質,成為細胞移動、接合等之基礎等。並且,亦發生血管新生,新生血管、纖維母細胞等之各種細胞、膠原蛋白等之細胞外基質混合的肉芽組織填充組織缺損部位。於以良好肉芽所覆蓋的傷口,進一步藉由角質細胞的移動而上皮化,並且藉由肌纖維母細胞之傷口收縮的2個機制,傷口面積逐漸縮小。如此一來創傷閉合成為(4)成熟期,形成斑痕組織。藉由細胞外基質之再塑造(remodeling)等之機制,最初帶有紅色的斑痕經過數個月變白而柔軟成熟化。所謂慢性損傷係指(1)至(4)中任一個過程發生障礙,延遲治癒,但多可視為(2)發炎期長期化、慢性化,亦即(2)移往(3)的障礙。於分子、細胞程度,認為此慢性發炎狀態係細胞異常、滲出液異常或細胞外基質異常等機制複合相關。因此,為脫離慢性發炎,迅速地移往(3)增殖期之治癒階段,調整傷口床環境係必要的。The healing process of trauma is generally performed by (1) bleeding clotting period, (2) inflammatory phase, (3) proliferative phase, and (4) maturation phase. (1) bleeding clotting phase is stopped by coagulation factor or platelet, and platelet A proliferative factor ‧ cytokine such as a platelet-derived proliferation factor is released. Next, (2) the inflammatory phase causes infiltration of inflammatory cells such as neutrophils or macrophage, and phagocytosis of necrotic tissue to cleanse the wound. At the same time, it can be seen that the cells further continuously release the proliferation factor ‧ cytokines such as transforming growth factor-β (TGF-β) or fibroblast growth factor (FGF). In addition, in order to melt necrotic tissue proteins, proteases such as matrix metalloproteinase (MMP) are also released. As the wound is cleaned, it moves to the (3) proliferative phase. (2) The factors released in the stage promote the movement and proliferation of fibroblasts or keratinocytes. The extracellular matrix represented by collagen is synthesized from fibroblasts, and becomes a basis for cell migration, bonding, and the like. In addition, angiogenesis, granulation tissue mixed with various cells such as neovascularization and fibroblasts, and extracellular matrices such as collagen are also filled with tissue-defective sites. The wound covered with good granulation is further epithelialized by the movement of keratinocytes, and the wound area is gradually reduced by the two mechanisms of wound contraction of myofibroblasts. As a result, the wound closure becomes (4) maturity and the formation of scar tissue. By the mechanism of remodeling of the extracellular matrix, the initial reddish marks become white and soft and mature after several months of whitening. Chronic injury refers to the occurrence of any one of (1) to (4), delaying the cure, but it can be seen as (2) long-term and chronic inflammatory phase, that is, (2) the disorder to (3). At the molecular and cellular levels, it is considered that this chronic inflammatory state is associated with a combination of cell abnormalities, abnormal exudates, or abnormalities of extracellular matrix. Therefore, in order to break away from chronic inflammation and rapidly move to the healing stage of the (3) proliferative phase, it is necessary to adjust the wound bed environment.
如此地若不調整傷口床環境,治癒不進行,皮膚創傷傷口殘留異物時,將導致發炎或感染,殘留壞死組織會使傷口下方貯存滲出液,形成膿腫,而難以評估實際創傷的深度。因此,實施清創手術(debridement)係直接與滲出液管理及控制感染有關。If the wound bed environment is not adjusted and the cure is not carried out, the skin wounds will cause inflammation or infection when the residual foreign matter remains. The residual necrotic tissue will store the exudate under the wound, forming an abscess, and it is difficult to assess the depth of the actual wound. Therefore, the implementation of debridement is directly related to the management of exudates and the control of infection.
於無活性的組織或不良肉芽、受到障礙的組織、嚴重的菌叢生長(Critical colonization,治癒停止,生物體免疫反應之發炎的初期狀態)中存在的生物被膜等係與治癒延緩深深有關。因此,已知清拭創傷、去除壞死組織、去除滲出液、去除不良肉芽、去除生物被膜等,對創傷或皮膚疾病之治癒過程係重要的,此等治療,尤其清拭創傷、去除壞死組織及去除不良肉芽等,可使用水凝膠或軟膏劑等。Biofilms and the like which are present in inactive tissues or defective granules, tissues that are affected by disorders, severe colonic growth (in the initial state of inflammation, and the initial state of inflammation of the biological immune response) are deeply involved in the delay of healing. Therefore, it is known that wiping wounds, removing necrotic tissue, removing exudate, removing bad granulation, removing biofilm, etc., are important for the healing process of wounds or skin diseases, especially for wiping wounds, removing necrotic tissue and A hydrogel or an ointment or the like can be used to remove bad granulation and the like.
傳統的薄片狀水凝膠(PVA水凝膠等)係製劑中含大量的精製水,使用於期待使壞死組織等浸軟等之自我融解作用,但因為無自黏性及伸縮性,所以難以使用於彎曲部位或伸屈部位,因吸水性低,所以滲出液等蓄積,而有使包含創傷邊緣等之健康皮膚浸軟之缺點(專利文獻1)。The conventional flaky hydrogel (PVA hydrogel, etc.) preparation contains a large amount of purified water, and is used for self-melting action such as softening of necrotic tissue or the like, but it is difficult to be self-adhesive and stretchable. When it is used for a curved portion or an extensible portion, the water absorption is low, so that the exudate or the like accumulates, and there is a disadvantage that the healthy skin including the wound edge is soaked (Patent Document 1).
關於凝膠狀的水凝膠,對於囊袋形成創傷等之治療尤其有效,但有去除時亦可能需要外科的清創手術(Debridement)等之缺點。Regarding the gel-like hydrogel, it is particularly effective for the treatment of a capsular bag to form a wound or the like, but there may be a disadvantage of surgical debridement or the like when it is removed.
對於軟膏劑,使用摻合蛋白質分解酵素製劑[摻合fradiomycin sulfate‧胰蛋白酶(francetin)、fradiomycin粉末、胰蛋白酶(胰蛋白酶粉末)、摻合鳳梨酵素(Bromelain)、摻合鏈激酶(streptokinase)‧鏈道酶(streptodornase)(Varidase)或溶纖維蛋白酵素(fibrinolysin)‧去氧核醣核酸酶(deoxyribonuclease)摻合劑(elase、elase-C)]於去除壞死組織等,但因引起對藥物過敏症或周圍皮膚之接觸性皮膚炎或浸軟,所以亦有必須以凡士林等保護創傷周圍的健康皮膚等之缺點。For ointments, use a blended proteolytic enzyme preparation [blend fradiomycin sulfate ‧ francetin, fradiomycin powder, trypsin (trypsin powder), blended Bromelain, blended streptokinase ‧ Streptodornase (Varidase) or fibrinolysin ‧ deoxyribonuclease (elase, elase-C) in the removal of necrotic tissue, etc., but caused by drug allergy or The skin around the skin is dermatitis or macerated, so it is necessary to protect the skin around the wound with Vaseline or the like.
另外,創傷治癒的延遲因子之一,認為於潰瘍表面因細菌形成的生物被膜,但傳統以來,雖對此等使用消毒劑或抗菌外用劑,但發現消毒劑會因細胞毒性而延緩創傷治癒,抗菌劑則有耐性菌發生等之缺點。In addition, one of the delay factors for wound healing is considered to be a biofilm formed by bacteria on the surface of the ulcer, but conventionally, although a disinfectant or an antibacterial external preparation has been used, it has been found that the disinfectant delays wound healing due to cytotoxicity. Antibacterial agents have disadvantages such as the occurrence of resistant bacteria.
另一方面,對於物理治療(冷凍療法、雷射治療、光線治療、超音波治療、切除等)後或化學治療(水楊酸、一氯乙酸、戊二醛、苯酚、乙醇等之去皮療法)後之去除病變或軟化、具有大量的滲出液或壞死組織等之皮膚癌之處理等,一般使用紗布、海綿、水膠體(hydrocolloid)、聚胺基甲酸酯、水凝膠、塞棉、其他纖維材料及軟膏劑。On the other hand, after physical therapy (cryotherapy, laser therapy, phototherapy, ultrasound therapy, resection, etc.) or chemotherapy (salicylation of salicylic acid, monochloroacetic acid, glutaraldehyde, phenol, ethanol, etc.) After the removal of lesions or softening, treatment of skin cancer with a large amount of exudate or necrotic tissue, etc., generally used gauze, sponge, hydrocolloid, polyurethane, hydrogel, cotton, Other fiber materials and ointments.
尤其是不能切除的乳癌或上顎癌、皮膚轉移癌、其他皮膚露出自壞的惡性腫瘤的處理係進行投予具有抗菌及抗潰瘍效果等之軟膏劑或以紗布或其他纖維材料等被覆。然而,紗布或其他纖維材料雖由毛細管現象吸收液體,但因為吸收的血液或滲出液乾固,或此等纖維埋入該組織,所以去除纖維材料時,扯裂組織,不少發生莫大的痛苦,同時並發生出血。In particular, breast cancer, breast cancer, skin metastases, and other malignant tumors in which the skin is exposed to the unresectable treatment are administered with an ointment having an antibacterial and anti-ulcer effect, or coated with gauze or other fibrous material. However, gauze or other fibrous materials absorb liquid by capillary action, but because the absorbed blood or exudate is dry, or these fibers are buried in the tissue, when the fibrous material is removed, the tissue is torn, and many pains occur. At the same time, bleeding occurred.
傳統的水凝膠或聚胺基甲酸酯薄膜等,因為吸水性低,所以有患處以及周圍健康皮膚浸軟之缺點。Conventional hydrogels or polyurethane films have the disadvantage of being soaked in the affected area and surrounding healthy skin because of low water absorption.
水膠體係藉由疏水性基劑中所含之親水性膠體粒子膨潤而吸收滲出液,但容易因吸水而形狀崩壞,交換時殘留凝膠狀物質於患處。另外,多為半透明至不透明物,難以觀察創傷表面,進而因為黏著力強,交換時伴隨疼痛亦不少,有發生剝離刺激之虞。The water-gel system absorbs the exudate by swelling the hydrophilic colloidal particles contained in the hydrophobic base, but is liable to collapse due to water absorption, and the gel-like substance remains in the affected part during exchange. In addition, it is mostly translucent to opaque, it is difficult to observe the surface of the wound, and because of the strong adhesion, there is a lot of pain accompanying the exchange, and there is a tendency to cause peeling stimulation.
聚胺基甲酸酯泡沫雖吸收大量的滲出液,但於滲出液多之創傷管理時,有患處以及周圍皮膚容易浸軟以及感染的缺點。Although the polyurethane foam absorbs a large amount of exudate, it has the disadvantage that the affected area and the surrounding skin are easily soaked and infected when the exudate is administered with a large amount of exudate.
自黏性之聚胺基甲酸酯薄膜,亦即,於胺基甲酸酯薄膜上塗佈丙烯酸系黏著劑之創傷被覆材料,雖然伸縮性非常優異,但因為幾乎無吸收性,所以應用於滲出液滲出之創傷表面時,因容易發生液體蓄積,所以必須排水。另外,因為黏著力亦強,所以不僅交換時伴隨著疼痛,亦有損傷已再生皮膚之虞(專利文獻2、3、4)。A self-adhesive polyurethane film, that is, a wound coating material coated with an acrylic adhesive on a urethane film, although excellent in stretchability, it is applied to almost no absorption. When the exudate leaks out of the wound surface, it is easy to cause liquid accumulation, so it is necessary to drain. In addition, since the adhesive force is also strong, not only the pain is exchanged, but also the skin that has regenerated the skin is damaged (Patent Documents 2, 3, and 4).
褐藻酸鹽凝膠雖然止血性、吸收性佳,但因滲出液而凝膠化,所以交換時創傷表面容易殘留凝膠狀物質,並且因為係開放系,所以為維持濕潤、防止細菌侵入、防止細菌增殖,必須以薄膜材料覆蓋等。(專利文獻5)Although the alginate gel is excellent in hemostatic property and absorbability, it gels due to exudate. Therefore, the gelled substance is likely to remain on the surface of the wound during exchange, and since it is open, it is moisturized and prevents invasion and prevention of bacteria. Bacterial proliferation must be covered with a film material. (Patent Document 5)
根據上述,期待具有自黏性、伸縮性佳,具有滲出液吸收性、維持濕潤環境佳、具有軟化、去除壞死組織或痂皮以及去除因細菌所形成的生物被膜等之作用,調整傷口床環境作用佳之創傷用水凝膠薄片。According to the above, it is expected to have a self-adhesive property, a good stretchability, an exudate absorption property, a good moisturizing environment, a softening, removal of necrotic tissue or suede, and removal of a biofilm formed by bacteria, etc., and adjustment of the wound bed environment. A good wound hydrogel sheet.
[專利文獻1]特許第3773983號公報[Patent Document 1] Patent No. 3773883
[專利文獻2]特開昭58-87153號公報[Patent Document 2] JP-A-58-87153
[專利文獻3]特開平4-272765號公報[Patent Document 3] JP-A-4-272765
[專利文獻4]特開2006-61263號公報[Patent Document 4] JP-A-2006-61263
[專利文獻5]特開平8-187280號公報[Patent Document 5] JP-A-8-187280
本發明係解決傳統以來的問題,提供去除痂皮、壞死組織或因細菌所形成之生物被膜或抑制創傷部位之細菌數量以及調整滲出液等之調節傷口床環境之作用佳,而且無交換時疼痛或損傷再生皮膚之虞之創傷用水凝膠薄片以及其利用方法。The present invention solves the conventional problem and provides a good effect of removing the molting, necrotic tissue or the biofilm formed by the bacteria or inhibiting the number of bacteria in the wound site and adjusting the environment of the wound bed, etc., and the pain is not exchanged. Or a wound hydrogel sheet that damages the skin after regeneration and its utilization method.
為解決前述課題,本發明者等進行努力探討的結果,發現塗佈含有水溶性高分子、甘油及水而成之水凝膠於由聚胺基甲酸酯薄膜及疏水性纖維所成之2層層合薄膜,其透濕度為200~2000(g/m2/24h),而且創傷用水凝膠薄片係去除痂皮、壞死組織或因細菌所形成之生物被膜以及調整滲出液等之調節傷口床環境之作用佳,無交換時疼痛或損傷再生皮膚之虞而完成本發明。In order to solve the above-mentioned problems, the inventors of the present invention have found that the hydrogel formed by coating a water-soluble polymer, glycerin, and water is formed of a polyurethane film and a hydrophobic fiber. a laminated film having a moisture permeability of 200 to 2000 (g/m 2 /24h), and the wound hydrogel sheet is used to remove the skin, the necrotic tissue or the biofilm formed by the bacteria, and the adjusted wound of the exudate. The bed environment works well and the present invention is completed without pain or damage to the skin during exchange.
亦即,本發明係以下述型態表示。That is, the present invention is represented by the following types.
(1)使用水凝膠薄片為特徵之皮膚創傷患處之傷口床環境調整用薄片。(1) A sheet for adjusting the wound bed environment of a skin wound affected area characterized by using a hydrogel sheet.
(2)前述(1)記載之薄片中,傷口床環境調整係去除於皮膚創傷患處因細菌所形成之生物被膜。(2) In the sheet according to (1) above, the wound bed environment adjustment is a biofilm formed by bacteria which is removed from the skin wound site.
(3)前述(1)記載之薄片中,傷口床環境調整係自感染創傷去除細菌及/或自預測會有感染之創傷去除細菌及/或抑制細菌生長發育。(3) In the sheet according to the above (1), the wound bed environment adjustment system removes bacteria from the wound wound and/or removes bacteria from the wound which is predicted to have an infection and/or inhibits bacterial growth and development.
(4)前述(1)至(3)中任一項記載之薄片中,水凝膠薄片係塗佈含有水溶性高分子、甘油及水之水凝膠於由聚胺基甲酸酯薄膜及疏水性纖維所成之2層層合薄膜而成之水凝膠薄片,且其透濕度為200~2000(g/m2/24h)。(4) The sheet according to any one of the above (1) to (3), wherein the hydrogel sheet is coated with a hydrogel containing a water-soluble polymer, glycerin and water, and a polyurethane film and A hydrogel sheet formed by laminating two layers of a hydrophobic fiber and having a moisture permeability of 200 to 2000 (g/m 2 /24 h).
(5)使用水凝膠薄片,進行皮膚創傷患處之傷口床環境調整為特徵之創傷的治療方法。(5) A method of treating a wound characterized by a wound bed environment in which a skin wound is affected by using a hydrogel sheet.
(6)使用水凝膠薄片,去除於皮膚創傷患處因細菌所形成之生物被膜為特徵之前述(5)記載之創傷的治療方法。(6) A method for treating a wound described in the above (5), which is characterized by using a hydrogel sheet to remove a biofilm formed by bacteria in a skin wound site.
(7)使用水凝膠薄片,自感染創傷去除細菌及/或自預測會有感染之創傷去除細菌及/或抑制細菌生長發育為特徵之前述(5)記載之創傷的治療方法。(7) A method for treating a wound according to the above (5), characterized in that the hydrogel sheet is used to remove bacteria from the wound and/or the bacteria are removed from the wound which is predicted to be infected, and/or the growth of the bacteria is inhibited.
(8)前述(5)至(7)中任一項記載之創傷的治療方法中,水凝膠薄片係塗佈含有水溶性高分子、甘油及水之水凝膠於由聚胺基甲酸酯薄膜及疏水性纖維所成之2層層合薄膜而成之水凝膠薄片,且其透濕度為200~2000(g/m2/24h)。(8) The method for treating a wound according to any one of the above (5), wherein the hydrogel sheet is coated with a hydrogel containing a water-soluble polymer, glycerin and water, and a polyaminocarbamic acid. A hydrogel sheet formed by laminating two layers of an ester film and a hydrophobic fiber, and having a moisture permeability of 200 to 2000 (g/m 2 /24 h).
(9)使用水凝膠薄片,於皮膚創傷患處,予以調整傷口床環境為特徵之創傷治療劑。(9) Using a hydrogel sheet, a wound healing agent characterized by adjusting the environment of the wound bed is applied to the affected area of the skin wound.
(10)使用水凝膠薄片,去除於皮膚創傷患處因細菌所形成之生物被膜為特徵之前述(9)記載之創傷治療劑。(10) A wound healing agent according to the above (9), characterized in that the biofilm is used to remove a biofilm formed by bacteria in a skin wound site.
(11)使用水凝膠薄片,自感染創傷去除細菌及/或自預測會有感染之創傷去除細菌及/或抑制細菌生長發育為特徵之前述(9)記載之創傷治療劑。(11) A wound therapeutic agent according to the above (9), characterized in that the hydrogel sheet is used to remove bacteria from an infectious wound and/or to remove bacteria from an infected wound and/or to inhibit bacterial growth and development.
(12)前述(9)至(11)中任一項記載之創傷治療劑,水凝膠薄片係塗佈含有水溶性高分子、甘油及水之水凝膠於由聚胺基甲酸酯薄膜及疏水性纖維所成之2層層合薄膜而成之水凝膠薄片,且其透濕度為200~2000(g/m2/24h)。(12) The wound therapeutic agent according to any one of the above (9), wherein the hydrogel sheet is coated with a hydrogel containing a water-soluble polymer, glycerin and water in a polyurethane film. And a hydrogel sheet formed by laminating two layers of a hydrophobic fiber, and having a moisture permeability of 200 to 2000 (g/m 2 /24h).
本發明之創傷用水凝膠薄片係去除痂皮、壞死組織或不良肉芽、吸收滲出液。進而,具有去除傷口表面的細菌生物被膜或細菌、或抑制細菌增殖的作用,以調整傷口床環境促進創傷治癒。另一方面,吸收滲出液,保持適當的濕潤環境,並且防止創傷邊緣部份健康皮膚的浸軟。亦即,此創傷用水凝膠薄片的主要用途係藉由緩和地去除具有痂皮或壞死組織等創傷之痂皮或壞死組織、緩和地去除於細菌生物被膜或感染傷口之細菌(抗菌作用)、預防急性創傷之細菌增殖以及藉由從垂直方向排出來自創傷表面的滲出液,不使包含傷口邊緣的健康皮膚浸軟而維持適當的濕潤環境,防止障礙或感染,健全化傷口,藉此傷口床環境調整等之創傷管理變得容易,可使創傷朝向治癒。另外,此創傷用水凝膠薄片亦有效地去除對於皮膚疾病等之物理治療、化學治療處理後之病變等。相關的創傷用水凝膠薄片,通常係藉由自袋中取出,貼附於創傷,而可清拭創傷、去除壞死組織、吸收創傷滲出液、抑制感染、調整傷口床、促進治癒。The wound hydrogel sheet of the present invention removes molting, necrotic tissue or defective granulation, and absorbs exudate. Further, it has the effect of removing the bacterial biofilm or bacteria of the wound surface or inhibiting the proliferation of the bacteria to adjust the wound bed environment to promote wound healing. On the other hand, the exudate is absorbed, a proper moist environment is maintained, and the skin of the wound is prevented from macerating. That is, the main use of the wound hydrogel sheet is to gently remove the wounded molting or necrotic tissue such as suede or necrotic tissue, gently remove the bacteria biofilm or infect the wound bacteria (antibacterial action), Proliferation of bacteria against acute trauma and by excretion of exudate from the surface of the wound from the vertical direction, so as not to weaken healthy skin containing the edge of the wound, maintain a proper moist environment, prevent obstacles or infections, and refine the wound, thereby making the wound bed Trauma management such as environmental adjustment becomes easy, and the wound can be cured. Further, the wound hydrogel sheet is also effective for removing physical diseases such as skin diseases and diseases after chemotherapeutic treatment. The related wound hydrogel sheets are usually attached to the wound by taking out from the bag, and can wipe the wound, remove the necrotic tissue, absorb the wound exudate, inhibit the infection, adjust the wound bed, and promote healing.
以下係更詳細地說明本發明。The invention is illustrated in more detail below.
本發明之水凝膠薄片,其透濕度係以200~2000(g/m2/24h)為宜,以500~1500(g/m2/24h)尤佳。透濕度未滿200(g/m2/24h)時,有因悶濕而發生皮膚刺激之虞,並不適宜。另外,大於2000(g/m2/24h)時,變得不能長時間維持創傷表面於適當的濕潤環境,並不適宜。The hydrogel sheet of the present invention preferably has a moisture permeability of from 200 to 2,000 (g/m 2 /24h), more preferably from 500 to 1,500 (g/m 2 /24h). When the moisture permeability is less than 200 (g/m 2 /24h), skin irritation due to stuffiness may occur, which is not suitable. Further, when it is more than 2000 (g/m 2 /24h), it is not suitable to maintain the wound surface in a proper moist environment for a long time.
本發明之構成聚胺基甲酸酯薄膜之聚胺基甲酸酯樹脂係可使用醚系、酯系等一般的聚胺基甲酸酯樹脂,並無特別的限制。The polyurethane resin constituting the polyurethane film of the present invention can be a general polyurethane resin such as an ether system or an ester system, and is not particularly limited.
本發明所使用之聚胺基甲酸酯薄膜之厚度為5~25μm,固定荷重伸長率為5%以上。The polyurethane film used in the present invention has a thickness of 5 to 25 μm and a fixed load elongation of 5% or more.
聚胺基甲酸酯薄膜的厚度未滿5μm時,機械強度不足及因針孔增大而不能維持創傷表面於適當的濕潤環境,所以不適宜。相反地,若比25μm厚時,固定荷重伸長率將未滿5%,損及伸縮性,所以變得難以保護創傷表面。另外,因亦降低透明性,所以變得不能觀察創傷表面,並不適宜。When the thickness of the polyurethane film is less than 5 μm, the mechanical strength is insufficient and the pinhole is increased, and the wound surface cannot be maintained in a proper wet environment, which is not preferable. On the other hand, when it is thicker than 25 μm, the fixed load elongation is less than 5%, and the stretchability is impaired, so that it is difficult to protect the wound surface. In addition, since the transparency is also lowered, it is not suitable to observe the wound surface.
作為層合於聚胺基甲酸酯薄膜的疏水性纖維,可使用聚酯、尼龍、丙烯酸樹脂、聚丙烯、聚乙烯等。As the hydrophobic fiber laminated to the polyurethane film, polyester, nylon, acrylic resin, polypropylene, polyethylene, or the like can be used.
如此所製作之由聚胺基甲酸酯薄膜及疏水性纖維所成之2層層合薄膜之透濕度,為長時間保持適合促進創傷表面治癒之濕潤環境,以於200~5000(g/m2/24h)之範圍內為宜,以300~3000(g/m2/24h)尤佳。透濕度若大於5000(g/m2/24h)時,不能長時間保持濕潤環境,促進創傷表面治癒的效果降低。另外,未滿200(g/m2/24h)時,有因悶濕而發生皮膚刺激之虞,並不適宜。The moisture permeability of the two-layer laminated film made of the polyurethane film and the hydrophobic fiber thus produced is a moist environment suitable for promoting healing of the wound surface for a long time, and is 200 to 5000 (g/m). It is preferably within the range of 2 / 24h), preferably 300 to 3000 (g/m 2 /24h). When the moisture permeability is more than 5000 (g/m 2 /24h), the wet environment cannot be maintained for a long time, and the effect of healing the wound surface is lowered. In addition, when it is less than 200 (g/m 2 /24h), skin irritation due to stuffiness may occur, and it is not suitable.
作為水溶性高分子,例如明膠、水解明膠、聚丙烯酸、聚丙烯酸鈉、聚丙烯酸部份中和物、聚丙烯酸澱粉、聚乙烯醇、聚乙烯吡咯烷酮、羥丙基纖維素、羥丙基甲基纖維素、羥乙基纖維素、甲基纖維素、羧甲基纖維素鈉(Carmellose Sodium)、羧乙烯基聚合物、甲氧基乙烯馬來酸酐共聚物、N-乙烯乙醯胺共聚物、黃原膠(Xanthan Gum)、阿拉伯膠等,可單獨或組合2種以上使用,但以聚丙烯酸、聚丙烯酸部份中和物及羧甲基纖維素鈉之組合尤佳。As a water-soluble polymer, for example, gelatin, hydrolyzed gelatin, polyacrylic acid, sodium polyacrylate, polyacrylic acid partial neutralizer, polyacrylic acid starch, polyvinyl alcohol, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl group Cellulose, hydroxyethyl cellulose, methyl cellulose, Carmellose Sodium, carboxyvinyl polymer, methoxyethylene maleic anhydride copolymer, N-ethylene acetamide copolymer Xanthan Gum, gum arabic, etc. may be used alone or in combination of two or more, but a combination of polyacrylic acid, a polyacrylic acid partial neutralizer, and sodium carboxymethylcellulose is particularly preferred.
前述水溶性高分子於水凝膠薄片中之摻合量係相對於凝膠重量為3~20重量%,以5~15重量%尤佳。摻合量未滿3重量%時,凝膠黏度過低,將難以成形作為貼附劑,若超過20重量%時,水溶性高分子不能均勻地溶解於凝膠中,不能形成良好的凝膠,所以不適宜。The blending amount of the water-soluble polymer in the hydrogel sheet is 3 to 20% by weight based on the weight of the gel, and particularly preferably 5 to 15% by weight. When the blending amount is less than 3% by weight, the gel viscosity is too low, and it is difficult to form the adhesive as a patch. When it exceeds 20% by weight, the water-soluble polymer is not uniformly dissolved in the gel, and a good gel cannot be formed. So not suitable.
水凝膠薄片中水的摻合量係相對於凝膠重量為30~80重量%,以40~75重量%尤佳。含水量超過80重量%時,滲出液的吸收性降低,所以不適宜。另外,未滿30重量%時,黏著力變得過強,交換創傷被覆材料時,有疼痛或損傷再生皮膚之虞,或因為對皮膚的保濕性降低,所以變得不能維持適合於促進創傷表面治癒的濕潤環境,所以不適宜。The blending amount of water in the hydrogel sheet is 30 to 80% by weight based on the weight of the gel, and particularly preferably 40 to 75% by weight. When the water content exceeds 80% by weight, the absorbability of the exudate is lowered, which is not preferable. In addition, when the weight is less than 30% by weight, the adhesive force becomes too strong, and when the wound coating material is exchanged, there is pain or damage to regenerate the skin, or because the moisturizing property against the skin is lowered, it becomes impossible to maintain a surface suitable for promoting wounds. It is not suitable for curing the moist environment.
另外,水凝膠中甘油之摻合量係相對於凝膠重量為10~40重量%,以15~30重量%尤佳。水凝膠中甘油之摻合量未滿10重量%時,因為對皮膚的保濕性降低,所以變得不能維持適合於促進創傷表面治癒的濕潤環境。另外,水凝膠中甘油之摻合量若多於40重量%時,會發生不能維持於凝膠表面之甘油浮出的現象,發生貼附時發黏、黏著力降低之問題。Further, the blending amount of glycerin in the hydrogel is 10 to 40% by weight based on the weight of the gel, and particularly preferably 15 to 30% by weight. When the blending amount of glycerin in the hydrogel is less than 10% by weight, since the moisturizing property against the skin is lowered, it becomes impossible to maintain a moist environment suitable for promoting healing of the wound surface. When the amount of glycerin blended in the hydrogel is more than 40% by weight, glycerin which cannot be maintained on the surface of the gel may be released, and the problem of stickiness and adhesion at the time of attachment may occur.
對於構成水凝膠薄片之前述以外的組成,並無特別限制,例如可摻合賦形劑、保濕劑、安定化劑、交聯劑等。The composition other than the above which constitutes the hydrogel sheet is not particularly limited, and for example, an excipient, a moisturizer, a stabilizer, a crosslinking agent, or the like can be blended.
作為賦形劑,例如陶土、氧化鈦、矽酸酐、氧化鋅、膨潤土等,可單獨或組合2種以上使用。然而,貼附水凝膠薄片於創傷表面時,因有使水凝膠薄片具有透明性而可觀察創傷表面之必要性,所以以矽酸酐尤佳,其摻合量係相對於凝膠重量,以0.1~5重量%為宜。As the excipient, for example, clay, titanium oxide, phthalic anhydride, zinc oxide, bentonite or the like may be used alone or in combination of two or more. However, when the hydrogel sheet is attached to the wound surface, the necessity of observing the wound surface due to the transparency of the hydrogel sheet is particularly preferable, and the blending amount is based on the gel weight. It is preferably 0.1 to 5% by weight.
作為甘油以外的保濕劑,例如D-山梨糖醇液、1,3-丁二醇、二丙二醇、聚乙烯醇、聚丙二醇、DL-吡咯烷酮羧酸鈉液等,可單獨或組合2種以上使用,其摻合量係相對於凝膠重量,以10~30重量%為宜。The humectant other than glycerin, for example, D-sorbitol liquid, 1,3-butylene glycol, dipropylene glycol, polyvinyl alcohol, polypropylene glycol, sodium DL-pyrrolidone carboxylic acid, etc., may be used alone or in combination of two or more. The blending amount is preferably from 10 to 30% by weight based on the weight of the gel.
作為安定化劑,例如乙二胺四乙酸鹽、對羥基苯甲酸酯、酒石酸、生育醇醋酸酯、抗壞血酸、亞硫酸氫鈉等,可單獨或組合2種以上使用。另外,水凝膠薄片之pH,就皮膚刺激性觀點上,以pH3.5~6.5之範圍為宜,進而以pH4.0~5.5之範圍尤佳。As the stabilizer, for example, ethylenediaminetetraacetate, p-hydroxybenzoic acid ester, tartaric acid, tocopheryl acetate, ascorbic acid, sodium hydrogen sulfite, or the like may be used alone or in combination of two or more. Further, the pH of the hydrogel sheet is preferably in the range of pH 3.5 to 6.5 from the viewpoint of skin irritation, and more preferably in the range of pH 4.0 to 5.5.
作為交聯劑,例如乾燥氫氧化鋁凝膠、乙酸銨二氫氧化鋁(aluminum glycinate)、二羥胺基醋酸鋁(Dihydroxyaluminum aminoacetate)、合成鋁碳酸鎂(hydrotalcite)、鋁矽酸金屬鹽等之多價金屬化合物等,可單獨或組合2種以上使用。其摻合量雖依其種而異,但相對於凝膠重量,以0.001~1重量%為宜。As the crosslinking agent, for example, a dry aluminum hydroxide gel, aluminum glycol aluminum fluoride, dihydroxyaluminum aminoacetate, synthetic hydrotalcite, aluminosilicate metal salt, and the like The valence metal compound or the like may be used alone or in combination of two or more. Although the blending amount varies depending on the type thereof, it is preferably 0.001 to 1% by weight based on the weight of the gel.
另外,因應需要,可進一步摻合防腐劑、抗氧化劑、可塑劑、乳化劑、界面活性劑等。Further, a preservative, an antioxidant, a plasticizer, an emulsifier, a surfactant, or the like may be further blended as needed.
本發明之水凝膠薄片,於使用於創傷部位時,可追隨皮膚動作之某程度黏著力係必要的,並且要求於其交換時,不損傷再生皮膚程度的黏著力。因此,使用本發明之水凝膠薄片時(吸水前)之黏著力係依據JIS Z0237之轉球(Ball Tack)試驗法進行,於傾斜角30°之轉球試驗法中之球號為8~12,交換時(吸水8小時後)之球號設定為3以下。使用時之球號若為8~12時,使用於創傷部位時,可具有可追隨皮膚動作之適當的黏著力。另外,若球號未滿8時,因為初期黏著力低,所以使用於可動創傷部位時,因為不能追隨皮膚動作,會發生立即剝落之問題,所以不適宜。另外,若超過12時,使用於創傷部位時,因黏著力過強,有引起皮膚刺激的可能性,並不適宜。另一方面,交換時的球號若為3以下係無交換時的疼痛或損傷再生皮膚的黏著力,若超過3時,因黏著力過高,有交換時的疼痛或損傷再生皮膚的可能性,並不適宜。The hydrogel sheet of the present invention, when applied to a wound site, is required to follow a certain degree of adhesion of the skin action, and is required to be adhered without impairing the adhesion of the regenerated skin. Therefore, when the hydrogel sheet of the present invention is used (before water absorption), the adhesion is carried out in accordance with the Ball Tack test method of JIS Z0237, and the ball number in the ball test method at an inclination angle of 30° is 8 to 12. When the ball is exchanged (after 8 hours of water absorption), the ball number is set to 3 or less. When the ball number at the time of use is 8 to 12, when used in a wound site, it can have an appropriate adhesive force that can follow the action of the skin. Further, when the ball number is less than 8, since the initial adhesive force is low, when it is used in the movable wound site, since the skin action cannot be followed, the problem of immediate peeling occurs, which is not preferable. Further, when it exceeds 12, when it is used in a wound site, the adhesion is too strong, and there is a possibility that skin irritation may occur, which is not preferable. On the other hand, if the ball number at the time of exchange is 3 or less, there is no pain during exchange or the adhesion of the damaged skin. If it exceeds 3, the adhesion is too high, and there is a possibility of pain or damage during skin exchange. Not suitable.
作為被覆水凝膠薄片表面之塑膠薄膜,可使用聚乙烯、聚丙烯、聚酯、聚氯化乙烯或將此等之表面經矽處理、電暈放電處理、凹凸處理、電漿處理等者。As the plastic film covering the surface of the hydrogel sheet, polyethylene, polypropylene, polyester, polyvinyl chloride or the like, such as enamel treatment, corona discharge treatment, uneven treatment, plasma treatment, or the like can be used.
本發明之水凝膠薄片的製造方法,並無特別的限定,可以已知的製造方法製造。例如藉由塗佈如前述構成所組成之水凝膠於支持體上,以塑膠薄膜被覆於水凝膠表面,可成形水凝膠薄片。The method for producing the hydrogel sheet of the present invention is not particularly limited, and it can be produced by a known production method. For example, a hydrogel sheet can be formed by coating a hydrogel composed of the above-described constitution on a support and coating a surface of the hydrogel with a plastic film.
因應需要,可進行通常所進行之滅菌方法之放射線滅菌、電子束滅菌、環氧乙烷滅菌等。Radiation sterilization, electron beam sterilization, ethylene oxide sterilization, etc., which are usually performed, may be performed as needed.
以下係表示實施例及比較例,更具體地說明本發明,但本發明並非局限於此等實施例者。The present invention will be more specifically described by way of examples and comparative examples, but the present invention is not limited to the examples.
溶解1.6g之羧乙烯基聚合物於適量的精製水後,加入20g之D-山梨糖醇液,混合至均勻。再將0.3g之聚丙烯酸、1.2g之酒石酸、20.7g之濃甘油、3.5g之羧甲基纖維素鈉(Carmellose Sodium)、4g之聚丙烯酸部份中和物、0.1g之矽酸酐、1.5g之萞麻油、0.07g之二羥胺基醋酸鋁、0.08g之乙二胺四乙酸鈉、適量的精製水,混合均勻,調製水凝膠。將此水凝膠塗佈於20μm胺基甲酸酯/25g尼龍彈性體/m2上,藉由以聚酯薄膜被覆凝膠表面,成形水凝膠薄片。After dissolving 1.6 g of the carboxyvinyl polymer in an appropriate amount of purified water, 20 g of the D-sorbitol solution was added and mixed until homogeneous. Further, 0.3 g of polyacrylic acid, 1.2 g of tartaric acid, 20.7 g of concentrated glycerin, 3.5 g of sodium carboxymethylcellulose (Carmellose Sodium), 4 g of polyacrylic acid partial neutralizer, 0.1 g of phthalic anhydride, 1.5 g of castor oil, 0.07 g of dihydroxyaminoacetic acid aluminum acetate, 0.08 g of sodium ethylenediaminetetraacetate, an appropriate amount of purified water, and uniformly mixed to prepare a hydrogel. This hydrogel was coated on 20 μm urethane/25 g nylon elastomer/m 2 , and the hydrogel sheet was formed by coating the surface of the gel with a polyester film.
水凝膠之調製方法係與實施例1相同,塗佈於將支持體變更成20μm胺基甲酸酯/尼龍針織物(tricot)上,藉由以聚酯薄膜被覆凝膠表面,成形水凝膠薄片。The hydrogel was prepared in the same manner as in Example 1 and applied to a support of 20 μm urethane/nylon knitted fabric, and the surface of the gel was coated with a polyester film to form a hydrogel. Glue sheet.
溶解0.5g之矽酸酐於適量的精製水後,加入1.0g之尿素、0.08g之乙二胺四乙酸鈉、0.5g之萞麻油,混合至均勻。再將15.0g之20%之聚丙烯酸水溶液、0.3g之酒石酸、16.0之濃甘油、4.0g之羧甲基纖維素鈉(Carmellose Sodium)、5.0g之聚丙烯酸部份中和物、0.06g之矽酸鎂鋁、0.02g之乾燥氫氧化鋁凝膠、適量的精製水,混合均勻,調製水凝膠。將此水凝膠塗佈於20μm胺基甲酸酯/25g尼龍彈性體/m2上,藉由以聚酯薄膜被覆凝膠表面,成形水凝膠薄片。After dissolving 0.5 g of phthalic anhydride in an appropriate amount of purified water, 1.0 g of urea, 0.08 g of sodium ethylenediaminetetraacetate, and 0.5 g of castor oil were added and mixed until homogeneous. Further, 15.0 g of a 20% aqueous solution of polyacrylic acid, 0.3 g of tartaric acid, 16.0 concentrated glycerin, 4.0 g of sodium carboxymethylcellulose (Carmellose Sodium), 5.0 g of a polyacrylic acid partial neutralized product, 0.06 g of Magnesium aluminum silicate, 0.02 g of dry aluminum hydroxide gel, and an appropriate amount of purified water were uniformly mixed to prepare a hydrogel. This hydrogel was coated on 20 μm urethane/25 g nylon elastomer/m 2 , and the hydrogel sheet was formed by coating the surface of the gel with a polyester film.
比較例3:「DuoACTIVE ET」ConvaTec製、水膠體創傷被覆材料Comparative Example 3: "DuoACTIVE ET" ConvaTec, hydrocolloid wound covering material
比較例4:「Opsite」Smith&Nephew製、聚胺基甲酸酯創傷被覆材料Comparative Example 4: "Opsite" Smith & Nephew, polyurethane wound coating material
比較例5:「Bugel」Nichiban製、PVA水凝膠創傷被覆材料Comparative Example 5: "Bugel" Nichiban, PVA hydrogel wound coating material
比較例6:「Tegaderm」3M公司製、水膠體被覆材料Comparative Example 6: "Tegaderm" 3M company, hydrocolloid coating material
使用實施例1~3之水凝膠薄片、及比較例1~5所得之創傷被覆材料,依據下述試驗方法測定伸縮性、透濕性、吸水性、黏著力。測定值係各測定3次,求其平均值者。結果如表2所示。Using the hydrogel sheets of Examples 1 to 3 and the wound coating materials obtained in Comparative Examples 1 to 5, the stretchability, moisture permeability, water absorbability, and adhesion were measured in accordance with the following test methods. The measurement values were measured three times each, and the average value was obtained. The results are shown in Table 2.
伸縮性試驗係依據JIS L1096之一般織物試驗方法之伸縮織物而實施。The stretch test was carried out in accordance with the stretch fabric of the general fabric test method of JIS L1096.
裁斷試驗材料成2×6cm,間隔4cm做記號(L0)。線的外側以夾具(clip)固定,施以100g固定荷重,測定記號間的距離(L1),由下式算出伸長率。Cut the test material into 2 × 6 cm, and mark 4 cm at intervals (L 0 ). The outer side of the wire was fixed by a clip, and a fixed load of 100 g was applied, and the distance (L 1 ) between the marks was measured, and the elongation was calculated from the following formula.
伸長率(%)=(L1-L0)/L0×100Elongation (%) = (L 1 - L 0 ) / L 0 × 100
L0:原本的記號間長度(4cm)L 0 : the length of the original mark (4cm)
L1:施以100g固定荷重時之記號間長度(cm)L 1 : length between marks (cm) when a fixed load of 100 g is applied
透濕性試驗係依據JIS Z0208之杯式法而實施。The moisture permeability test was carried out in accordance with the cup method of JIS Z0208.
放入約10ml的精製水於玻璃杯容器(內徑:56mm,深度11mm),裁斷試驗材料成直徑80mm圓形(試驗片),以膏體面為內側,覆蓋玻璃容器開口處,以鏈烷烴系伸縮薄膜密封玻璃容器端,測定此重量(W0)。Put about 10ml of purified water in a glass container (inner diameter: 56mm, depth 11mm), cut the test material into a circular shape (test piece) with a diameter of 80mm, with the paste surface inside, covering the opening of the glass container, with paraffin The stretch film seals the end of the glass container and the weight (W 0 ) is measured.
接著,靜置於40℃-75%之恆溫恆濕器24小時,精密地測定放冷後之重量(W1),由下式算出透濕度。Subsequently, the mixture was placed in a thermo-hygrostat at 40 ° C to 75% for 24 hours, and the weight (W 1 ) after cooling was accurately measured, and the moisture permeability was calculated from the following formula.
透濕度(g/m2‧24h)=(W1-W0)×10000÷AMoisture permeability (g/m 2 ‧24h)=(W 1 -W 0 )×10000÷A
W0:試驗前重量(g)W 0 : pre-test weight (g)
W1:試驗後重量(g)W 1 : weight after test (g)
A:玻璃容器開口處的面積(26.4cm2)A: Area of the opening of the glass container (26.4 cm 2 )
放入約10ml的生理食鹽水於不銹鋼容器(內徑:88mm,深度15mm),裁斷試驗材料成4×4cm(試驗片),以膏體面為內側,以密封於容器內之狀態,保存8小時。比較放入容器內之前的試驗片重量(W0)與8小時後取出的試驗片重量(W1)。Put about 10ml of physiological saline in a stainless steel container (inner diameter: 88mm, depth 15mm), cut the test material into 4 × 4cm (test piece), with the paste surface as the inner side, sealed in the container, and stored for 8 hours. . The weight (W 0 ) of the test piece before being placed in the container and the weight (W 1 ) of the test piece taken out after 8 hours were compared.
吸收量:W1-W0 Absorption: W 1 -W 0
使用醫藥品製造販賣指針2005(第IV部醫藥品之製造販賣承認申請,第1章 黏著力試驗)記載之試驗器,以試驗製劑之黏著面向上,放置於對水平成30度之斜面上。以適當的紙覆蓋上方10cm,下方15cm的部份,中央留著5cm的黏著面。The tester described in the Pharmaceutical Manufacturing Sales and Marketing Guide 2005 (Approval of Manufacturing and Sales of Pharmaceuticals, Part IV, Adhesive Test, Chapter 1 Adhesion Test) is placed on the inclined surface at 30 degrees to the horizontal with the adhesive surface of the test preparation facing upward. Cover the upper 10 cm and the lower 15 cm with appropriate paper, and keep a 5 cm adhesive surface in the center.
將直徑3.2mm~34.9mm之一系列錫球,由斜面上端滾動,測定停止於中央黏著面5秒以上之球號數。A series of solder balls having a diameter of 3.2 mm to 34.9 mm were rolled from the inclined surface, and the number of balls stopped at the center adhesive surface for 5 seconds or more was measured.
以此評估吸水前及吸水8小時後之製劑。This was used to evaluate the preparation before water absorption and after 8 hours of water absorption.
依據JIS L1099纖維製品之透濕度試驗方法,以氯化鈣法(A-1法,40℃-90%RH)測定實施例1~3及比較例1~2使用的支持體之透濕度,結果如表3所示。The moisture permeability of the supports used in Examples 1 to 3 and Comparative Examples 1 and 2 was measured by the calcium chloride method (A-1 method, 40 ° C - 90% RH) according to the moisture permeability test method of JIS L1099 fiber product. as shown in Table 3.
貼附實施例1~3之水凝膠薄片及比較例1、3、4所得之創傷被覆材料於弄濕的海綿上。放入該海綿於37℃溫水循環之不銹鋼容器。進而,於水凝膠薄片或創傷被覆材料與海綿之間,夾入溫濕度感應器,測定貼附部位的溫濕度變化至開始後60分,以及接著經時地測定至24小時。各結果如圖1及圖2所示。The hydrogel sheets of Examples 1 to 3 and the wound coating materials obtained in Comparative Examples 1, 3, and 4 were attached to a wet sponge. A stainless steel container in which the sponge was circulated at 37 ° C in warm water. Further, a temperature and humidity sensor was sandwiched between the hydrogel sheet or the wound covering material and the sponge, and the temperature and humidity of the attached portion were measured to change to 60 minutes after the start, and then measured to 24 hours. The results are shown in Figures 1 and 2.
貼附實施例1~3之水凝膠薄片、及市售品之比較例3~5所得之創傷被覆材料於5位志願者的前腕4小時,依據下述基準,進行皮膚黏著性及剝離時疼痛的評估。The hydrogel sheets of Examples 1 to 3 and the wound coating materials obtained in Comparative Examples 3 to 5 of the commercial products were attached to the front wrist of 5 volunteers for 4 hours, and the skin adhesion and peeling were performed according to the following criteria. Assessment of pain.
對於皮膚黏著性,進行「未剝離」、「剝離一半」、「已剝離」之3階段評估,結果如表4表示。For the skin adhesion, a three-stage evaluation of "not peeled off", "half peeled off", and "detached" was performed, and the results are shown in Table 4.
對於自皮膚剝離時的疼痛,進行「完全不痛」、「不太感到疼痛」、「疼痛」之3階段評估,結果如表5表示。For the pain from skin peeling, a three-stage evaluation of "no pain at all", "no pain", and "pain" was performed, and the results are shown in Table 5.
貼附實施例2所得之創傷用水凝膠薄片於大鼠(n=3)背部製作的痂皮形成後的分層缺損部位,貼附8小時後剝離,將去除痂皮的狀況,進行「被覆材料黏著於患處或殘留75%以上的痂皮」「剝離時要用力(可見到疼痛的動作)或殘留50%以上的痂皮」「可簡單地剝離,並且幾乎無痂皮殘留」的3階段評估。其結果係貼附實施例2薄片8小時,無訴說疼痛,僅剝離即可簡便地自傷口去除痂皮等。結果如以下表6所示。The wound hydrogel sheet obtained in Example 2 was attached to the layered defect portion after the formation of the suede on the back of the rat (n=3), and was peeled off after 8 hours of attachment, and the condition of the suede was removed to perform "coating." The material adheres to the affected area or remains more than 75% of the suede. "Strike force (visible pain action) or 50% or more of suede remaining" "can be easily peeled off and almost no suede residue" Evaluation. As a result, the sheet of Example 2 was attached for 8 hours, and no pain was reported, and peeling and the like were easily removed from the wound. The results are shown in Table 6 below.
1:可簡單地剝離,並且幾乎無痂皮殘留。1: It can be easily peeled off and almost no suede remains.
2:剝離時要用力(可見到疼痛的動作)或殘留50%以上的痂皮2: Forced when peeling (visible pain action) or more than 50% residual suede
3:被覆材料黏著於患處或殘留75%以上的痂皮3: The coated material adheres to the affected area or more than 75% of the suede remains.
若貼附於乾燥的痂皮8小時,則痂皮軟化,剝離貼附劑時一同簡單地剝離。When it is attached to the dried suede for 8 hours, the suede is softened, and the peeling agent is simply peeled off together.
試驗例5中投予前之痂皮及剝離後之創傷傷口的狀態,以及剝離後實施例2之水凝膠狀態如圖3、圖4及圖5所示。The state of the wound before the administration of the suede and the peeling before the administration in Test Example 5, and the state of the hydrogel of Example 2 after the peeling are shown in Figs. 3, 4 and 5.
於24隻小鼠之綠膿菌感染傷口,每隔48小時交換、貼附實施例1之水凝膠薄片及市售品之比較例6所得之創傷被覆材料,對於受傷5天後組織中細菌數、創傷收縮率及上皮伸長,進行評估。該結果係藉由減少感染傷傷及極限帶菌狀態之細菌數,防止對健康皮膚傷害下維持創傷的濕潤環境,防止創傷之難治化。進而,認為藉由調整創傷治癒環境,促進創傷治癒。In the wounds of P. aeruginosa infected in 24 mice, the hydrogel sheets of Example 1 and the wound coating materials obtained in Comparative Example 6 of the commercial product were exchanged every 48 hours, and the bacteria in the tissues after 5 days of injury. The number, wound contraction rate, and epithelial elongation were evaluated. The result is to prevent the wounds from being damaged by healthy skin and to prevent the wound from becoming refractory by reducing the number of bacteria in the infected wounds and the ultimate bacteria state. Furthermore, it is considered that wound healing can be promoted by adjusting the wound healing environment.
採取患處組織,測定重量後,進行細菌培養,測定菌數。After taking the affected tissue and measuring the weight, the bacteria were cultured and the number of bacteria was measured.
其結果係如圖6所示,實施例1與比較例6相比較,細菌數有意義地減少,認為對感染創傷及極限帶菌狀態之創傷具有有效性。As a result, as shown in Fig. 6, in Comparative Example 1, the number of bacteria was significantly reduced as compared with Comparative Example 6, and it was considered to be effective for wounds in infected wounds and in the state of ultimate infection.
測定患處之表皮創傷邊緣間隙的距離,由下式算出創傷收縮率。The distance between the epidermal wound margins of the affected area was measured, and the wound contraction rate was calculated from the following formula.
創傷收縮率(%)=表皮創傷邊緣間隙的距離/創傷邊之毛囊間的距離×100Wound contraction rate (%) = distance between the epidermal wound edge gap / distance between the wound edges of the hair follicle × 100
其結果係如圖7所示,實施例1與比較例6相比較,認為創傷面積收縮,認為促進創傷治癒。As a result, as shown in Fig. 7, in Example 1, compared with Comparative Example 6, it was considered that the wound area was shrunk, and it was considered that the wound healing was promoted.
測定患處創傷邊毛囊至表皮創傷邊緣的距離,求出上皮伸長。The distance from the wound edge hair follicle to the edge of the epidermal wound was measured to determine the epithelial elongation.
其結果係如圖8所示,實施例1與比較例6相比較,認為更多上皮伸長,認為促進創傷治癒。As a result, as shown in Fig. 8, in Example 1, compared with Comparative Example 6, it was considered that the epithelial elongation was more, and it was considered that the wound healing was promoted.
測定受創第3天及第5天創傷周圍皮膚浸軟的面積。The area of skin maceration around the wound on the 3rd and 5th day of the wound was measured.
其結果係如圖9所示,比較例6與實施例1相比較,皮膚逐漸浸軟,認為皮膚的浸軟面積有意義差異。進而,與實施例1隨著時間經過,浸軟面積減少相比較,比較例4浸軟面積增加。由此認為實施例1藉由從垂直方向排出來自創傷表面的滲出液,防止因浸軟對創傷周圍健康皮膚的損傷,同時減輕感染的風險。As a result, as shown in Fig. 9, in Comparative Example 6, the skin was gradually softened as compared with Example 1, and it was considered that the skin's macerated area was significantly different. Further, in Comparative Example 1, as compared with the decrease in the dip area as time elapsed, the softened area of Comparative Example 4 increased. From this, it is considered that Example 1 prevents exudation from the wound surface by the vertical direction, thereby preventing damage to healthy skin around the wound due to maceration, and at the same time reducing the risk of infection.
本發明之創傷用水凝膠薄片的主要用途係藉由緩和地去除具有痂皮或壞死組織等之創傷之痂皮或壞死組織、緩和地去除細菌生物被膜或感染創傷之細菌(抗菌作用)、以及藉由從垂直方向排出來自創傷表面的滲出液,不使包含傷口邊緣的健康皮膚浸軟而維持適當的濕潤環境,維持適當的濕潤環境,健全化傷口床,藉此建立使創傷朝向治癒之創傷管理,對於感染創傷或新鮮外傷、手術創傷、燙湯及褥瘡之滲出液多的創傷治療有效。The main use of the wound hydrogel sheet of the present invention is to gently remove the wounded molting or necrotic tissue having ecdy or necrotic tissue, gently remove the bacterial biofilm or the wound-infected bacteria (antibacterial action), and By expelling the exudate from the wound surface in a vertical direction, the healthy skin containing the wound edge is not softened, maintaining a proper moist environment, maintaining a proper moist environment, and reaping the wound bed, thereby establishing a wound that causes the wound to be cured. Management, effective for trauma treatment of wounds or fresh trauma, surgical trauma, hot soup and acne exudate.
[圖1]表示局部濕度變化(1小時)。[Fig. 1] shows a local humidity change (1 hour).
[圖2]表示局部濕度變化(24小時)。[Fig. 2] shows a local humidity change (24 hours).
[圖3]表示投予水凝膠薄片前之大鼠痂皮的狀態。Fig. 3 is a view showing a state of rat skin before administration of a hydrogel sheet.
[圖4]表示水凝膠薄片剝離後之大鼠創傷處的狀態。Fig. 4 shows the state of the wound portion of the rat after the hydrogel sheet was peeled off.
[圖5]表示剝離後之實施例2之水凝膠薄片的狀態。Fig. 5 shows the state of the hydrogel sheet of Example 2 after peeling.
[圖6]表示小鼠創傷組織中之細菌數。Fig. 6 shows the number of bacteria in mouse wound tissue.
[圖7]表示創傷收縮率。Fig. 7 shows the rate of wound contraction.
[圖8]表示上皮伸長。[Fig. 8] shows epithelial elongation.
[圖9]表示周圍皮膚之浸軟面積。[Fig. 9] shows the macerated area of the surrounding skin.
Claims (3)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010208928 | 2010-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201217005A TW201217005A (en) | 2012-05-01 |
TWI600438B true TWI600438B (en) | 2017-10-01 |
Family
ID=45831527
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW100133462A TWI600438B (en) | 2010-09-17 | 2011-09-16 | Method of hydrogel sheet for wound |
Country Status (7)
Country | Link |
---|---|
US (1) | US9877871B2 (en) |
EP (1) | EP2617437B1 (en) |
JP (1) | JP5878870B2 (en) |
AU (1) | AU2011304133A1 (en) |
CA (1) | CA2811045C (en) |
TW (1) | TWI600438B (en) |
WO (1) | WO2012036064A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2973701B1 (en) * | 2011-04-06 | 2013-10-04 | Biopass S A | COMPOSITION FOR TOPICAL APPLICATION |
US10470936B2 (en) | 2012-02-29 | 2019-11-12 | Hollister Incorporated | Buffered adhesive compositions for skin-adhering medical products |
AU2013226154B2 (en) | 2012-02-29 | 2015-07-09 | Hollister Incorporated | Buffered adhesive compositions for skin-adhering products and methods of making same |
JP6215541B2 (en) * | 2013-02-28 | 2017-10-18 | 国立大学法人 東京大学 | Method for producing gel fiber assembly having bundle structure |
WO2015054377A2 (en) * | 2013-10-08 | 2015-04-16 | University Of Massachusetts | Essential oils or volatile organics thereof electrospun in chitosan nanofiber mats |
CN108273115B (en) * | 2018-04-16 | 2020-06-16 | 山东威高药业股份有限公司 | Application of hydroxyethyl starch in preparation of wound dressing |
JP7389418B2 (en) * | 2019-02-18 | 2023-11-30 | 青葉化成株式会社 | hemostatic agent |
CN112426561A (en) * | 2020-10-26 | 2021-03-02 | 上海迪派生物科技有限公司 | Hydrogel with continuous antibacterial ability |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009107189A1 (en) * | 2008-02-25 | 2009-09-03 | 帝國製薬株式会社 | Wound-covering hydrogel material |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4415628A (en) | 1981-10-26 | 1983-11-15 | Seton Company | Moisture vapor permeable sheet materials |
JPH04272765A (en) | 1991-02-27 | 1992-09-29 | Terumo Corp | Adhesive dressing |
GB2291348B (en) | 1994-07-18 | 1999-01-20 | Johnson & Johnson Medical | Sterile gel composition for wound treatment comprising alginate and polyhydric alcohol |
US5846214A (en) | 1996-03-29 | 1998-12-08 | Nichiban Company Limited | PVA hydrogel, hydrogel laminate using the same and hydrogel wound-dressing material using the same |
EP1051982A1 (en) | 1999-05-10 | 2000-11-15 | The Procter & Gamble Company | Hydrogel pressure sensitive adhesives for use as wound dressings |
WO2001015750A1 (en) | 1999-08-27 | 2001-03-08 | Department Of National Defence | Hydrogel wound dressing containing liposome-encapsulated therapeutic agent |
CA2576040A1 (en) | 2003-10-21 | 2005-04-28 | Bioartificial Gel Technologies Inc. | Hydrogel-containing medical articles and methods of using and making the same |
JP4594677B2 (en) | 2004-08-25 | 2010-12-08 | 新タック化成株式会社 | Adhesive film dressing |
EP1917047B1 (en) | 2005-07-14 | 2019-09-04 | First Water Limited | Treatment of chronic ulcerous skin lesions |
MX2009005783A (en) * | 2006-12-01 | 2009-10-28 | Laclede Inc | Use of hydrolytic and oxidative enzymes to dissolve biofilm in ears. |
GB0715198D0 (en) | 2007-08-06 | 2007-09-12 | First Water Ltd | A Wound dressing |
US9242022B2 (en) * | 2008-01-18 | 2016-01-26 | 3M Innovative Properties Company | Hydrogels with tapered edge |
GB201000916D0 (en) * | 2010-01-21 | 2010-03-10 | Adv Med Solutions Ltd | Treatment of biofilms |
-
2011
- 2011-09-08 AU AU2011304133A patent/AU2011304133A1/en not_active Abandoned
- 2011-09-08 JP JP2012533969A patent/JP5878870B2/en active Active
- 2011-09-08 US US13/823,220 patent/US9877871B2/en active Active
- 2011-09-08 CA CA2811045A patent/CA2811045C/en active Active
- 2011-09-08 WO PCT/JP2011/070461 patent/WO2012036064A1/en active Application Filing
- 2011-09-08 EP EP11825067.9A patent/EP2617437B1/en active Active
- 2011-09-16 TW TW100133462A patent/TWI600438B/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009107189A1 (en) * | 2008-02-25 | 2009-09-03 | 帝國製薬株式会社 | Wound-covering hydrogel material |
Also Published As
Publication number | Publication date |
---|---|
TW201217005A (en) | 2012-05-01 |
CA2811045C (en) | 2021-01-12 |
EP2617437A1 (en) | 2013-07-24 |
US9877871B2 (en) | 2018-01-30 |
CA2811045A1 (en) | 2012-03-22 |
EP2617437A4 (en) | 2014-09-17 |
WO2012036064A1 (en) | 2012-03-22 |
JP5878870B2 (en) | 2016-03-08 |
US20130211309A1 (en) | 2013-08-15 |
JPWO2012036064A1 (en) | 2014-02-03 |
EP2617437B1 (en) | 2018-10-24 |
AU2011304133A1 (en) | 2013-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI600438B (en) | Method of hydrogel sheet for wound | |
Peng et al. | Recent progress of collagen, chitosan, alginate and other hydrogels in skin repair and wound dressing applications | |
Gruppuso et al. | Polymeric wound dressings, an insight into polysaccharide-based electrospun membranes | |
Mir et al. | Synthetic polymeric biomaterials for wound healing: a review | |
Boateng et al. | Wound healing dressings and drug delivery systems: a review | |
JP5160081B2 (en) | Wound dressings containing oxidized cellulose and human recombinant collagen | |
Kus et al. | Wound dressings–a practical review | |
WO2009107189A1 (en) | Wound-covering hydrogel material | |
EP1341561B1 (en) | Dressings for the treatment of exuding wounds | |
JP5788323B2 (en) | Interfacial layer wound dressing | |
Chopra et al. | Strategies and therapies for wound healing: a review | |
US20060111657A1 (en) | Wound treatment device | |
JP2005511147A (en) | Controlled release wound dressing | |
KR20110114195A (en) | Hydrogel patch mixed inorganic materials for pets, and their process | |
US20070020318A1 (en) | Hydrocolloid materials for use in wound healing | |
EP1601388B1 (en) | Hydrocolloid materials for use in wound healing | |
JP4808402B2 (en) | Wound dressing material containing a complex of anionic polysaccharide and silver | |
Bhoyar et al. | Dressing materials: A comprehensive review | |
JP5147207B2 (en) | Hydrogel wound dressing | |
Buyana et al. | Antibiotics encapsulated scaffolds as potential wound dressings | |
Aderibigbe | Efficacy of Polymer-Based Wound Dressings in Chronic Wounds | |
KR20200124679A (en) | Multilayer composite material | |
Sonar et al. | A Comprehensive review on wound dressing usage in clinical settings | |
TWI429462B (en) | Hydrogel wound dressing | |
Kumar et al. | New frontiers in wound-dressings: An interdisciplinary perspective |